Inactive Instrument

News Mount Magnet South Ltd Australian S.E.

Stocks

AU000000MUM1

Biotechnology & Medical Research

End-of-day quote Australian S.E.
- ^AUD	-

08-25	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
08-11	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI

All News

Mentions Relevance

08-25	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
08-25	Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X	AQ
08-11	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI
08-11	Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026	AQ
07-23	Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea	CI
07-23	Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea	AQ
06-25	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT
06-25	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ
06-10	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility	AQ
06-09	Incannex Announces Initiation of Research Coverage by Alliance Global Partners	AQ
05-15	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI
05-15	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-14	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea	RE
05-14	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea	AQ
05-14	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea	CI
05-12	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development	AQ
04-22	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness	AQ
04-22	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints	CI
03-27	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position	RE
03-27	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position	AQ
03-25	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation	CI
03-25	Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research	AQ
03-18	Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development	AQ
03-17	Incannex regains compliance with Nasdaq minimum bid price requirement	RE